Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: Interactions with mTOR inhibitors

British Journal of Pharmacology

Volumn 143, Issue 3, 2004, Pages 388-396

  Christians, Uwe ^a   Gottschalk, Sven ^b   Miljus, Jelena ^a,b   Hainz, Carsten ^a   Benet, Leslie Z ^c   Leibfritz, Dieter ^b   Serkova, Natalie ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF BREMEN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclosporine; Everolimus; Glucose metabolism; Glycolysis; Metabolomics; Mitochondrial energy production; MRS; Oxidative stress; Sirolimus

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCINEURIN INHIBITOR; CARBON 13; CREATINE PHOSPHATE; CYCLOSPORIN; EVEROLIMUS; GLUCOSE; GLUTAMIC ACID; IMMUNOSUPPRESSIVE AGENT; LACTIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; PHOSPHORUS 31; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; TARGET OF RAPAMYCIN KINASE;

ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; BRAIN MITOCHONDRION; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; GLUCOSE METABOLISM; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; BRAIN; CARBON ISOTOPES; CYCLOSPORINE; DRUG INTERACTIONS; ENERGY METABOLISM; GLUCOSE; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; NAD; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PERFUSION; PHOSPHOCREATINE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SIROLIMUS; TIME FACTORS;

EID: 7044236807     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705939     Document Type: Article

References (39)

1. ANDOH, T.F., LINDSLEY, J., FRANCESCHINI, N. & BENNETT, W.M. (1996). Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation. 62, 311-316.
2. AUPETIT, B., GHAZI, A., BLANCHOUIN, N., TOURY, R., SHECHTER, E. & LEGRAND, J.-C. (1988). Impact on energy metabolism of quantitative and functional cyclosporine-induced damage of kidney mitochondria. Biochim. Biophys. Acta, 936, 325-331.
3. BAI, S., BRUNNER, L.J., STEPKOWSKI, S.M., NAPOLI, K.M. & KAHAN, B.D. (2001). Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat. Transplantation. 71, 1585-1592.
4. BECHSTEIN, W.O. (2000). Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant. Int., 13, 313-326.
5. CRUZ, F. & WOLF, A. (2001). Effects of the novel cyclosporine derivative PSC833 on glucose metabolism in rat primary cultures of neuronal and glial cells. Biochem. Pharmacol., 62, 129-139.
6. DIAS, V.C., MADSEN, K.L., MULDER, K.E., KEELAN, M., YATSCOFF, R.W. & THOMSON, A.B. (1998). Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits. Dig. Dis. Sci., 43, 2227-2236.
7. ERECINSKA, M. & WILSON, D.F. (1982). Regulation of cellular energy metabolism. J. Membr. Biol., 70, 1-14.
8. FAULDS, D., GOA, K.L. & BENFIELD, P. (1993). Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs, 45, 953-1040.
9. GIJTENBEEK, J.M., VAN DEN BENT, M.J. & VECHT, C.J. (1999). Cyclosporine neurotoxicity. J. Neurol., 246, 339-346.
10. GUMMERT, J.F., IKONEN, T. & MORRIS, R.E. (1999). Newer immunosuppressive drugs: a review. J. Am. Soc. Nephrol., 10, 1366-1380.
11. 31P-NMR studies of isolated adult heart cells: effect of myoglobin inactivation. Am. J. Physiol., 261, H1155-H1163.
12. 1H NMR spectroscopic studies of liver extracts of carbon tetrachloride-treated rats. NMR Biomed., 12, 395-401.
13. KAHAN, B.D. (1989). Cyclosporine. N. Engl. J. Med., 321, 1725-1738.
14. KAHAN, B.D. (1997). The synergistic effects of cyclosporine and sirolimus. Transplantation, 63, 170.
15. KAHAN, B.D. (2000). Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. The Rapamune US Study Group. Lancet, 356, 194-202.
16. KAHAN, B.D. & KRAMER, W.O. (2001). Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin. Pharmacol. Ther., 70, 74-81.
17. KOVARIK, J.M., KAHAN, B.D., KAPLAN, B., LORBER, M., WINKLER, M., ROUILLY, M., GERBEAU, C., CAMBON, N., BOGER, R. & RORDORF, C. (2001). Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin. Pharmacol. Ther., 69, 48-56.
18. KOVARIK, J.M., KAPLAN, B., TEDESCO SILVA, H., KAHAN, B.D., DANTAL, J., VITKO, S., BOGER, R. & RORDORF, C. (2002). Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation, 72, 920-925.
19. LEIBFRITZ, D. (1996). An introduction to the potential of 1H-, 31P- and 13C-NMR spectroscopy. Anticancer Res., 16, 1317-1324.
20. MEYER, M.A. (2002). Elevated basal ganglia glucose metabolism in cyclosporine neurotoxicity: a positron emission tomography imaging study. J. Neuroimaging, 12, 92-93.
21. NASHAN, B. (2002). Early clinical experience with a novel rapamycin derivative. Ther. Drug Monitor., 24, 53-58.
22. NEUHAUS, P., KLUPP, J. & LANGREHR, J.M. (2001). mTOR inhibitors: an overview. Liver Transplant., 7, 473-484.
23. NICHOLSON, J.K. & WILSON, I.D. (2003). Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov., 8, 668-676.
24. PARRA, T., DE ARRIBA, G., CONEJO, J.R., CANTERO, M., ARRIBAS, I., RODRIGUEZ-PUYOL, D., RODRIGUEZ-PUYOL, M. & CARBALLO, F. (1998). Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats: effect of vitamin E on cyclosporine nephrotoxicity. Transplantation, 66, 1325-1329.
25. PODDER, H., STEPKOWSKI, S.M., NAPOLI, K.L., CLARK, J., VERANI, R.R., CHOU, T.C. & KAHAN, B.D. (2001). Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J. Am. Soc. Nephrol., 12, 1059-1071.
26. SCHREIBER, S.L. & CRABTREE, G.R. (1992). The mechanism of action of cyclosporin A and FK 506. Immunol. Today, 13, 136-142.
27. SCHUURMAN, H.J., COTTENS, S., FUCHS, S., JOERGENSEN, J., MEERLOO, T., SEDRANI, R., TANNER, M., ZENKE, G. & SCHULER, W. (1997). SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation, 64, 32-35.
28. SERKOVA, N. & CHRISTIANS, U. (2003). Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr. Opin. Investig. Drugs, 4, 1287-1296.
29. SERKOVA, N., DONOHOE, P., GOTTSCHALK, S., HAINZ, C., NIEMANN, C.U., BICKLER, P.E., LITT, L., BENET, L.Z., LEIBFRITZ, D. & CHRISTIANS, U. (2002). Comparison of the effects of cyclosporine A on the metabolism of perfused rat brain slices during normoxia and hypoxia. J. Cerebr. Blood Flow Metab., 22, 342-352.
30. SERKOVA, N., KLAWITTER, J. & NIEMANN, C.U. (2003). Organ-specific response to inhibition of mitochondrial metabolism by cyclosporine in the rat. Transplant. Int., 16, 748-755.
31. SERKOVA, N., LITT, L., JAMES, T.L., SADEE, W., LEIBFRITZ, D., BENET, L.Z. & CHRISTIANS, U. (1999). Evaluations of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J. Pharmacol. Exp. Ther., 289, 800-806.
32. SERKOVA, N., LITT, L., LEIBFRITZ, D., HAUSEN, B., MORRIS, R.E., JAMES, T.L., BENET, L.Z. & CHRISTIANS, U. (2000). The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br. J. Pharmacol., 129, 485-492.
33. SERKOVA, N., JACOBSEN, W., NIEMANN. C.U., BENET, L.Z., LEIBFRITZ, D. & CHRISTIANS, U. (2001). Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br. J. Pharmacol., 133, 875-885.
34. UEMOTO, S., TANAKA, K., ASONUMA, K., OKAMURA, R., KITAKADO, Y., MATSUOKA, S., OZAKI, N., OZAWA, K., HASHIDA, T., INUI, K. & HORI, R. (1989). Effect of cyclosporine on oxidative phosphorylation and adenylate energy charge of regenerating rat liver. Res. Exp. Med., 189, 313-320.
35. WANG, C. & SALAHUDEEN, A.K. (1994). Cyclosporine nephrotoxicity: attenuation by an antioxidant-inhibitor of lipid peroxidation in vitro and in vivo. Transplantation, 58, 940-946.
36. WANG, H. & JOSEPH, J.A. (1999). Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic. Biol. Med., 27, 612-616.
37. WANG, X., LUO, H., PERKS, A. & WU, J. (1996). Rapamycin inhibits aldolase A expression during human leukocytes activation. J. Cell. Biochem., 63, 239-251.
38. WIJDICKS, E.F. (2001). Neurotoxicity of immunosuppressive drugs. Liver Transplant., 7, 937-942.
39. WOLF, A., TRENDELENBURG, C.F., DIEZ-FERNANDEZ, C., PRIETO, P., HOUY, S., TROMMER, W.E. & CORDIER, A. (1997). Cyclosporine A-induced oxidative stress in rat hepatocytes. J. Pharmacol. Exp. Ther., 280, 1328-1334.